196 related articles for article (PubMed ID: 29090520)
21. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
22. Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Jiménez-Hernández E; Jaimes-Reyes EZ; Arellano-Galindo J; García-Jiménez X; Tiznado-García HM; Dueñas-González MT; Martínez Villegas O; Sánchez-Jara B; Bekker-Méndez VC; Ortíz-Torres MG; Ortíz-Fernández A; Marín-Palomares T; Mejía-Aranguré JM
Biomed Res Int; 2015; 2015():576950. PubMed ID: 25922837
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.
Waber DP; Silverman LB; Catania L; Mautz W; Rue M; Gelber RD; Levy DE; Goldwasser MA; Adams H; Dufresne A; Metzger V; Romero I; Tarbell NJ; Dalton VK; Sallan SE
J Clin Oncol; 2004 Jul; 22(13):2701-7. PubMed ID: 15226337
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
25. The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Elbjeirami WM; Alieldin N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):320-325. PubMed ID: 28343905
[TBL] [Abstract][Full Text] [Related]
26. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
27. Effects of Race/Ethnicity and Socioeconomic Status on Outcome in Childhood Acute Lymphoblastic Leukemia.
Acharya S; Hsieh S; Shinohara ET; DeWees T; Frangoul H; Perkins SM
J Pediatr Hematol Oncol; 2016 Jul; 38(5):350-4. PubMed ID: 27177145
[TBL] [Abstract][Full Text] [Related]
28. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
[TBL] [Abstract][Full Text] [Related]
29. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia.
Mogensen SS; Harila-Saari A; Mäkitie O; Myrberg IH; Niinimäki R; Vestli A; Hafsteinsdottir S; Griškevicius L; Saks K; Hallböök H; Retpen J; Helt LR; Toft N; Schmiegelow K; Frandsen TL;
Pediatr Blood Cancer; 2018 Oct; 65(10):e27300. PubMed ID: 29943905
[TBL] [Abstract][Full Text] [Related]
30. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
Waber DP; Turek J; Catania L; Stevenson K; Robaey P; Romero I; Adams H; Alyman C; Jandet-Brunet C; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2007 Nov; 25(31):4914-21. PubMed ID: 17971588
[TBL] [Abstract][Full Text] [Related]
31. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01.
Waber DP; Shapiro BL; Carpentieri SC; Gelber RD; Zou G; Dufresne A; Romero I; Tarbell NJ; Silverman LB; Sallan SE
Cancer; 2001 Jul; 92(1):15-22. PubMed ID: 11443604
[TBL] [Abstract][Full Text] [Related]
32. Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Gotti G; Stevenson K; Kay-Green S; Blonquist TM; Mantagos JS; Silverman LB; Place AE
Pediatr Blood Cancer; 2022 Apr; 69(4):e29542. PubMed ID: 35187841
[TBL] [Abstract][Full Text] [Related]
33. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
[TBL] [Abstract][Full Text] [Related]
34. Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico.
Jaime-Pérez JC; López-Razo ON; García-Arellano G; Pinzón-Uresti MA; Jiménez-Castillo RA; González-Llano O; Gómez-Almaguer D
Arch Med Res; 2016 Nov; 47(8):668-676. PubMed ID: 28476194
[TBL] [Abstract][Full Text] [Related]
35. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.
Schorin MA; Blattner S; Gelber RD; Tarbell NJ; Donnelly M; Dalton V; Cohen HJ; Sallan SE
J Clin Oncol; 1994 Apr; 12(4):740-7. PubMed ID: 8151317
[TBL] [Abstract][Full Text] [Related]
36. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
[TBL] [Abstract][Full Text] [Related]
37. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Asberg A; Helt LR; Frandsen T; Schmiegelow K
Eur J Haematol; 2016 Feb; 96(2):160-9. PubMed ID: 25867866
[TBL] [Abstract][Full Text] [Related]
38. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
39. [Acute lymphoblastic leukemia in childhood. A 10-year experience with the DFCI 81-01 protocol].
de Lacerda AF; Chagas M; Neto A; Vieira E; Ribeiro MJ; Pereira F; Ambrósio A; Sousinha M
Acta Med Port; 1999; 12(7-11):287-92. PubMed ID: 10707467
[TBL] [Abstract][Full Text] [Related]
40. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.
te Winkel ML; Pieters R; Hop WC; de Groot-Kruseman HA; Lequin MH; van der Sluis IM; Bökkerink JP; Leeuw JA; Bruin MC; Egeler RM; Veerman AJ; van den Heuvel-Eibrink MM
J Clin Oncol; 2011 Nov; 29(31):4143-50. PubMed ID: 21947829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
